Antimicrobial resistance among *Escherichia coli* that cause childhood community-acquired urinary tract infections in Northern Italy

Alessandra Caracciolo¹, Alberto Bettinelli²*, Claudio Bonato¹, Clementina Isimbaldi², Alessandro Tagliabue², Laura Longoni², Mario G Bianchetti³

**Abstracts**

**Background:** Resistance rate of *Escherichia coli* against antimicrobials that are commonly prescribed in pediatric urinary tract infections is currently a matter of concern.

**Methods:** The antimicrobial susceptibility patterns of uropathogenic *Escherichia coli* strains to the common antibacterials ampicillin, cotrimoxazole, coamoxyclav, ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin were determined in 177 children aged from 2 to 36 months. They presented with their first symptomatic community-acquired urinary tract infection at the Department of Pediatrics, San Leopoldo Mandic Hospital, Merate-Lecco.

**Results:** High rates of ampicillin (inpatients: 50%; outpatients: 52%) resistance were identified. The resistance for cotrimoxazole (inpatients: 22%; outpatients: 15%) and especially coamoxyclav (inpatients: 6%; outpatients: 10%) was less pronounced than that to ampicillin. No resistance or less than 1% of resistance was identified for ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin both in inpatients and in outpatients.

**Conclusions:** Italian children affected with a community acquired urinary tract infection are initially managed orally with coamoxyclav or parenterally with ceftriaxone. The results of the present retrospective analysis support this attitude. Parenteral ceftriaxone or an aminoglycoside should be considered for patients on antimicrobial prophylaxis or recently prescribed antimicrobials.

**Background**

Urinary tract infections are common bacterial infections of childhood [1,2]. Prompt recognition and correct antimicrobial management relieve symptoms and prevent kidney damage [1,2]. Since drug management is usually started before the responsible microorganism and its susceptibility to antimicrobial agents are known, the choice relies on local epidemiologic data. Considering that *Escherichia coli* accounts for 60 to 80% of community-acquired urinary tract infections, initial empiric therapy includes antimicrobial agents that provide coverage for that particular bacterium [1,2].

The results of a study performed between 2000 and 2005 in North East Italy indicate that both oral coamoxyclav and parenteral ceftriaxone are very effective in the management of childhood pyelonephritis [3]. Resistance to commonly prescribed antimicrobials agents, caused among others by the production of extended spectrum beta lactamases, is currently a matter of increasing concern [4]. We studied the susceptibility to antimicrobials of *Escherichia coli* strains that cause symptomatic community-acquired urinary tract infections in small children treated at our institution.

**Materials and methods**

The study is a retrospective analysis of bacteria isolated from urinary tract cultures performed during the 3-year period from 2007 to 2009 at the Department of Pediatrics, San Leopoldo Mandic Hospital, Merate (Lecco), a Northern Italy hospital.
We included exclusively children aged from 2 to 36 months presenting with their first symptomatic community-acquired urinary tract infection. Infants less than 6 months of age, toxic or ill appearing children, and patients unable to retain oral fluids were admitted for parenteral antimicrobial management. Uncertainty about outpatient adherence to the recommended regimen of care was a further indication for admission. Children with known urinary tract malformations or antimicrobial prophylaxis were excluded. In the patients urine, collected either by clean catch method or by bladder catheterization, contained 25 or more white cells per microliter, and the culture grew only one micro-organism and ≥ 100,000 colony forming units per milliliter (midstream collection) respectively ≥ 10,000 colony forming units per milliliter (transurethral catheterization).

Standard techniques were used for culture and identification of pathogens [5]. *Escherichia coli* susceptibility testing was performed using the disk diffusion technique according to the guidelines of the Clinical and Laboratory Standards Institute. Inhibition halo diameter was interpreted for each isolate to determine susceptibility, which was defined as susceptible, intermediate, or resistant [5]. Following common antimicrobials were tested: ampicillin, coamoxyclav, cotrimoxazole, ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin.

For analysis the two-tailed Fisher exact test was used [6]. Statistical significance was defined as a P value of < 0.05.

**Results**

During the study period, a total of 275 consecutive children, 145 (53%) girls and 130 (47%) boys between 2 and 36 months of age, were included. Urine had been obtained by clean catch method in 243 and by bladder catheterization in the remaining 32 children. Germs other than *Escherichia coli* caused the infection in 98 (36%) cases: *Proteus mirabilis* (N = 40; 15%), *Pseudomonas aeruginosa* (N = 19; 7%), Enterococcus species (N = 17; 6%), *Klebsiella pneumoniae* (N = 12; 4%), other uropathogens (N = 10; 4%).

*Escherichia coli* was isolated in the remaining 177 (64%) children. This germ was isolated in 153 of the 243 (63%) collections performed by clean catch method and in 24 of the 32 (75%) collections performed by bladder catheterization (difference not significant).

The antimicrobial susceptibility of isolated *Escherichia coli* strains appears in figure 1. Considering that uropathogenic *Escherichia coli* strains with intermediate susceptibility are considered clinically sensitive, high rates of ampicillin (inpatients: 34 cases, 50%; outpatients: 57 cases, 52%) resistance were identified. The resistance for cotrimoxazole (inpatients: 15 cases, 22%; outpatients: 16 cases, 15%) and especially coamoxyclav (inpatients: 4 cases, 6%; outpatients: 11 cases; 10%) was less pronounced than that to ampicillin. No resistance or less than 1% of resistance was identified for ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin both in inpatients and in outpatients. The resistance rate was not statistically different in inpatients as compared with outpatients.

Age distribution ranged between 2 and 12 months in 107 (60%) and between 13 and 36 months in the remaining 70 subjects (40%), as given in table 1. While the majority of children aged between 2 and 12 months were admitted, the majority of those aged between 13 and 36 months were not admitted (P < 0.001). Furthermore, while the majority of the children aged between 2 and 13 months were boys, the majority of those aged between 13 and 36 months were girls (P < 0.001). The antimicrobial susceptibility of isolated *Escherichia coli* strains was similar in both age groups.

**Discussion**

The results of the present analysis performed in small children with their first *Escherichia coli* community-acquired urinary tract infection confirm that these infections are more prevalent among males during the first year of life and among females thereafter [1,2]. Furthermore our data confirm that the resistance rate of *Escherichia coli* against cotrimoxazole and especially ampicillin, antimicrobials that are commonly prescribed in these children, is currently a matter of concern. On the contrary, resistance against coamoxyclav was uncommon. Finally, no significant resistance was noted against nitrofurantoin, third-generation cephalosporins like ceftazidime or ceftriaxone, and the established aminoglycoside gentamycin.

Antimicrobial resistance has reached crisis stage in human medicine [4]. The crucial factor underlying resistance is antimicrobial use within both human and veterinary medicine (the greater the duration of exposure, the greater the risk of the development of resistance irrespective of the severity of the need for antimicrobials). In the present analysis children on antimicrobial prophylaxis and patients with hospital acquired infections were not included: in these patients testing for resistance is biased towards higher rates of resistance [4]. However, we did not specifically address the possible prescription of antimicrobials in the weeks preceding the urinary tract infection, a further possible cause of reduced antimicrobial susceptibility [1,2].

In this study *Escherichia coli* was isolated more frequently in urine obtained by clean catch method than in urine obtained by bladder catheterization. This observation might suggest some degree of contamination in samples obtained without catheterization.

High resistance rates of *Escherichia coli* against ampicillin and cotrimoxazole have also been recently noted.
in various European countries, including Switzerland and Austria, indicating that management with these agents may be inadequate in many cases [7-9].

Susceptibility to nitrofurantoin has remained practically unchanged since its introduction into clinical practice more than 50 years ago [10]. Since standard medication with nitrofurantoin does not achieve therapeutic concentrations in the bloodstream, its use is advised only for uncomplicated cystitis [10]. Fluoroquinolones are widely prescribed to treat urinary tract infections in adulthood [11]. We did not address the susceptibility pattern of these drugs to *Escherichia coli*.

**Figure 1** Susceptibility to ampicillin, cotrimoxazole, coamoxyclav, ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin in 177 pediatric urinary tract infections caused by *Escherichia coli*. The affected children were treated either as inpatients (N = 68; 38%) or as outpatients (N = 109; 62%). Inpatients are given full colors, outpatient patterned colors. No difference was noted between inpatients and outpatients.

**Table 1** Influence of age on resistance to ampicillin, cotrimoxazole, and coamoxyclav in 177 pediatric urinary tract infections caused by *Escherichia coli*.

|                      | 2-12 Months of Age | 13-36 Months of Age | Significance |
|----------------------|--------------------|---------------------|--------------|
| N                    | 107                | 70                  |              |
| Gender, male: female | 57: 50             | 19: 51              | P < 0.001    |
| Inpatients/outpatients | 50/57             | 18/52               | P < 0.001    |
| *Escherichia coli* Resistance, N (%) |                  |                     |              |
| Ampicillin significant | 56 (52%)          | 35 (50%)           |              |
| Coamoxyclav significant | 6 (6%)           | 9 (13%)            |              |
| Cotrimoxazole significant | 16 (15%)         | 15 (21%)           |              |

No resistance or less than 1% of resistance was identified for ceftazidime, ceftriaxone, nitrofurantoin, and gentamycin.
because studies in juvenile laboratory animals suggest there may be an increased risk of fluoroquinolone-associated cartilage lesions [11].

Coamoxyclav is currently widely used and recommended [12] in Italy for the empirical oral management of children affected with a community acquired urinary tract infection. The rate of in vitro resistance to this antimicrobial noted in the present study performed between 2007 and 2009 is almost identical to that noted in North East in Italy between 2000 and 2005 [3]. Considering that coamoxyclav is concentrated in the urine and susceptibility testing is mostly based upon blood concentration determinations, this antimicrobial might often be effective for the treatment of urinary tract infections even when in vitro susceptibility testing suggests full resistance. On the other side, the very good susceptibility pattern of isolated Escherichia coli to third-generation cephalosporins and aminoglycosides support the current role of these drugs in the treatment of childhood urinary tract infection.

In this study, the susceptibility to antimicrobials was identical and age-independent in inpatients and outpatients with a community acquired urinary tract infection, as previously noted in the literature [1,2]. These observations suggest, that in uropathogens bacterial virulence that causes severe disease and, subsequently, increases the risk factor for hospitalization, is not related to susceptibility to antimicrobials.

Conclusions

The results of the present analysis support the recommendations of the Italian Society of Pediatric Nephrology to initially manage children affected with a community acquired urinary tract infection with either coamoxyclav or parenteral ceftriaxone. Parenteral ceftriaxone or an aminoglycoside should be considered for patients on antimicrobial prophylaxis or recently prescribed antimicrobials.

References

1. Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006, 53:379-400.
2. Helfenstein S. Acute urinary tract infection - evaluation and treatment. Curr Opin Pediatr 2006, 18:134-138.
3. Montini G, Toffolo A, Zucchetta P, Dall’Amico R, Gobber D, Calderan A, Maschio F, Pavanello L, Molinari PP, Scuronno D, Zanchettta S, Cassar W, Briosotto P, Consini A, Santori S, Da Dalt L, Muerl L, Zucchetello G. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 2007, 335:386-388.
4. Paschke AA, Zottius T, Conray P, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics 2010, 125:664-672.
5. Holland TL, Woods CW, Joyce M. Antibacterial susceptibility testing in the clinical laboratory. Infect Dis Clin North Am 2009, 23:757-790.
6. Brown GW, Hayden GF. Nonparametric methods. Clinical applications. Clin Pediatr (Phila) 1985, 24:490-498.
7. Bonari AG, Bucher B, Brazzola P, Simonetti GD, Dolina M, Bianchetti MG. Susceptibility of Escherichia coli strains isolated from outpatient children with community-acquired urinary tract infection in Southern Switzerland. Clin Ther 2008, 30:2100-2105.
8. Fritzsche M, Ammann RA, Droz S, Bianchetti MG, Aebi C. Changes in antimicrobial resistance of Escherichia coli causing urinary tract infections in hospitalized children. Eur J Microbiol Infect Dis 2005, 24:233-235.
9. Prelog M, Schiefecker D, Fille M, Wurzner R, Brunner A, Zimmerhackl LB. Febrile urinary tract infection in children: ampicillin and trimethoprim insufficient as empirical mono-therapy. Pediatr Nephrol 2008, 23:597-602.
10. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am 2006, 90:1089-1107.
11. Koyle MA, Barqawi A, Wild J, Passamanecchio M, Furness PD. Pediatric urinary tract infections: the role of fluoroquinolones. Pediatr Infect Dis J 2003, 22:1133-1137.
12. Montini G, Ammenti L, Cataldi L, Chimenz R, Fanos V, La Manna A, Mars G, Materassi M, Pecile P, Pennesi M, Pisanello L, Sica F, Toffolo A. Le infezioni febbrili delle vie urinarie. Medico e Bambino 2009, 28:359-370.

Cite this article as: Caracciolo et al.: Antimicrobial resistance among Escherichia coli that cause childhood community-acquired urinary tract infections in Northern Italy. Italian Journal of Pediatrics 2011 37:3.